Target intelligence / Profile preview

Neudesin neurotrophic factor pseudogene 1 (NENFP1)

Target: NENFP1
Molecular classification: Other

Overview

Neudesin neurotrophic factor pseudogene 1 (NENFP1) is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a gene but generally non-functional; it does not encode a functional protein product[2]. NENFP1 is related by sequence to the genuine neudesin neurotrophic factor gene (NENF), which encodes a secreted protein with neurotrophic activity[3][4][7]. However, as a pseudogene, NENFP1 itself is not transcribed into a biologically active protein and does not have a known physiological or pathological role[2][7]. There is no evidence that NENFP1 serves as a therapeutic target, is implicated in disease, or is associated with actionable biomarkers or known drug interactions.

Other names: NENFP1Neudesin neurotrophic factor pseudogene 1

Beyond the preview

Go deeper on Neudesin neurotrophic factor pseudogene 1 (NENFP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neudesin neurotrophic factor pseudogene 1 (NENFP1).

Explore the full profile